Immuron Limited ADR (IMRN)
NASDAQ: IMRNHealthcareBiotechnologyUSD
At close: Oct 8, 4:00 PM ET · Delayed 15 min
IMRN stock chart
Technical analysisKey statistics
All statistics- Market cap
- $8.96M
- EPS (TTM)
- -$0.34
- Dividend yield
- None
- 52-week range
- 0.677 – 2.39
- Day range
- 1.09 – 1.17
- Volume / Avg
- 34.19K / 2.06M
- Beta
- —
- Shares outstanding
- 8.07M
52-week range
IMRN stock today
Shares of Immuron (IMRN) finished higher on Oct 8 at $1.11, a gain of 1.83% or $0.02 per share, versus the S&P 500's 0.47% decline. Trading was light, with 34.19K shares changing hands, about 2% of the average daily volume. At this level, IMRN sits in the middle of its 52-week range of $0.677 to $2.39: 53.6% below the high and 64.0% above the low.
Immuron has posted a net loss over the last twelve months (EPS of -$0.34), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Immuron
Company profileImmuron Limited, a biopharmaceutical company, engages in the research, development, and commercialization of polyclonal antibodies for the treatment of inflammatory mediated and infectious diseases in Australia, the United States, and Canada. It operates through two segments, Research and Development; and Hyper-immune Products. The company offers Travelan, an over-the-counter medicine to reduce the risk of travelers' diarrhea and risk of minor gastrointestinal disorders, as well as a dietary supplement for digestive tract protection; ProIBS, an over the counter orally administered product containing the proprietary ingredient AVH200 for the treatment of irritable bowel syndrome; and Protectyn, an immune supplement to help maintain a healthy digestive function and liver.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Carlton, VIC
- Employees
- 7
- IPO year
- 2017
- Website
- immuron.com.au
Analyst forecast
ForecastConsensus
none
Avg. price target
$3.89+250.45%
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Immuron peers
Healthcare sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| JAGXJaguar Health Inc. | 4.53 | -9.40% | $8.81M | vs IMRN |
| MTVAMetaVia Inc. | 1.34 | -8.22% | $8.83M | vs IMRN |
| CALCCalciMedica Inc. | 1.30 | -12.16% | $8.88M | vs IMRN |
| ENSCEnsysce Biosciences Inc. | 0.458 | +6.66% | $8.91M | vs IMRN |
| MBRXMoleculin Biotech Inc. | 0.424 | -3.39% | $8.64M | vs IMRN |
| AZTRAzitra Inc | 0.132 | 0.00% | $8.00M | vs IMRN |
| CNSPCNS Pharmaceuticals Inc. | 5.35 | -1.47% | $7.82M | vs IMRN |
| FBLGFibroBiologics Inc. | 1.11 | -2.63% | $7.72M | vs IMRN |
Indexes, lists and sector
Appears in lists
Immuron stock FAQ
What is Immuron's stock price today?
IMRN last traded at $1.11 as of Oct 8, 4:00 PM EDT, up 1.83% on the day. Prices are delayed at least 15 minutes.
What is the IMRN 52-week high?
The 52-week high for IMRN is $2.39 and the 52-week low is $0.677. The stock is currently 53.6% below its high.